SCHEMBL1784560

SCHEMBL1784560

CCN(C)c1ccc(C(=O)O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
NPC1 O15118 2/20 0.52
MEN1 O00255 1/20 0.52
POLB P06746 1/20 0.52
KMT2A Q03164 1/20 0.52
TP53 P04637 1/20 0.50
TSHR P16473 1/20 0.50
ADRA2A P08913 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
RXRA P19793 3/20 0.45
RXRB P28702 3/20 0.45
RXRG P48443 2/20 0.45
HCAR3 P49019 3/20 0.45
SRD5A2 P31213 1/20 0.44
ALDH2 P05091 1/20 0.44
HPGD P15428 2/20 0.43
MAPT P10636 1/20 0.43
CA12 O43570 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18821758 0.89 NPC1 (0.70) ALDH1A1NPC1MEN1POLBKMT2A
SCHEMBL15722856 0.85 RAB9A (0.53) ALDH1A1NPC1MEN1POLBKMT2A
SCHEMBL82487 0.85 HPGD (0.61) ALDH1A1NPC1MEN1POLBKMT2A
SCHEMBL11146761 0.84 HCAR3 (0.58) ALDH1A1NPC1MEN1POLBKMT2A
SCHEMBL11800833 0.83 ADRA2A (0.47) ALDH1A1NPC1MEN1POLBKMT2A
Butane SCHEMBL2586584 0.83 NPC1 (0.67) ALDH1A1NPC1MEN1POLBKMT2A
SCHEMBL8350993 0.83 MAPT (0.54) ALDH1A1NPC1MEN1POLBKMT2A
SCHEMBL8633955 0.82 HPGD (0.67) ALDH1A1NPC1MEN1KMT2AADRA2A
SCHEMBL23247969 0.82 ADRA2A (0.46) ALDH1A1NPC1MEN1POLBKMT2A
SCHEMBL13331926 0.82 ADRA2A (0.55) ALDH1A1POLBKMT2ATSHRADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4314302-A1 TETRACYCLINE-INDUCIBLE EXPRESSION SYSTEMS DNA TWOPOINTO INC. (US) 2024-02-07 EP disclosed
US-20230323396-A1 TETRACYCLINE-INDUCIBLE EXPRESSION SYSTEM DNA TWOPOINTO INC. (US) 2023-10-12 US disclosed
US-11566262-B2 Tetracycline-inducible expression systems DNA TWOPOINTO INC. (US) 2023-01-31 US disclosed
US-10071027-B2 Dental composites OREGON HEALTH & SCIENCE UNIVERSITY (US) 2018-09-11 US disclosed
US-20170087062-A1 DENTAL COMPOSITES OREGON HEALTH & SCIENCE UNIVERSITY (US) 2017-03-30 US disclosed
US-20170014419-A1 MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) 2017-01-19 US disclosed
EP-1797186-B1 EXPRESSION SYSTEM, COMPONENTS THEREOF AND METHODS OF USE NAT RES COUNCIL CANADA (CA) 2016-05-25 EP disclosed
WO-2015142886-A1 DENTAL COMPOSITES OREGON HEALTH & SCIENCE UNIVERSITY (US) 2015-09-24 WO disclosed
US-8728759-B2 Reverse cumate repressor mutant NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2014-05-20 US disclosed
US-8476430-B2 Fused heterocyclic compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-02 US disclosed
US-20080311618-A1 Expression System, Components Thereof and Methods of Use NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2008-12-18 US disclosed
EP-1797186-A4 EXPRESSION SYSTEM, COMPONENTS THEREOF AND METHODS OF USE CA NAT RESEARCH COUNCIL (CA) 2008-11-12 EP disclosed
EP-1797186-A1 EXPRESSION SYSTEM, COMPONENTS THEREOF AND METHODS OF USE NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2007-06-20 EP disclosed
WO-2006037215-A1 EXPRESSION SYSTEM, COMPONENTS THEREOF AND METHODS OF USE NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2006-04-13 WO disclosed
WO-2006000085-A1 HEPATITIS C INHIBITOR PEPTIDE ANALOGS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-01-05 WO disclosed
US-20040205834-A1 System for inducible expression in eukaryotic cells NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2004-10-14 US disclosed
EP-1385946-A2 A SYSTEM FOR INDUCIBLE EXPRESSION IN EUKARYOTIC CELLS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2004-02-04 EP disclosed
WO-2002088346-A2 A SYSTEM FOR INDUCIBLE EXPRESSION IN EUKARYOTIC CELLS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2002-11-07 WO disclosed
US-4011173-A MODIFIED NEMATIC MIXTURES WITH POSITIVE DIELECTRIC ANISOTROPY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1977-03-08 US disclosed
US-3936462-A CNS DEPRESSANT, ANALGESIC STERLING DRUG INC. (US) 1976-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170087062-A1 DENTAL COMPOSITES TERT, ITGA8, TTPA ALDH1A1 182/4885NPC1 4257/4885MEN1 4331/4885
US-20170014419-A1 MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS AGTR2, MME, AGTR1 ALDH1A1 2036/4885NPC1 2415/4885MEN1 725/4885
US-10071027-B2 Dental composites TERT, ITGA8, TTPA ALDH1A1 182/4885NPC1 4257/4885MEN1 4331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.